EmpathogenStrong Evidence

MDMA

Also known as: Ecstasy, Molly, Methylenedioxymethamphetamine

MDMA is a synthetic empathogen that increases the release of serotonin, dopamine and norepinephrine. Unlike classic psychedelics, it mainly increases feelings of closeness and lowers fear, usually without hallucinations, which is why researchers have studied it alongside talk therapy for PTSD. In tw...

Applications

4

Clinical Trials

4

Evidence Tier

strong

Duration

3-5 hours peak effects, with aftereffects lasting 6-8 hours

Overview

MDMA is a synthetic empathogen that increases the release of serotonin, dopamine and norepinephrine. Unlike classic psychedelics, it mainly increases feelings of closeness and lowers fear, usually without hallucinations, which is why researchers have studied it alongside talk therapy for PTSD. In two Phase 3 trials run by MAPS and Lykos Therapeutics, about two thirds of participants who received MDMA with therapy no longer met the criteria for PTSD at the end of the study. In August 2024, FDA declined to approve it, citing concerns about study design, functional unblinding (most participants could tell whether they had received MDMA) and missing data, and asked for another Phase 3 trial. In August 2026 the company, now called Resilient Pharmaceuticals, was reported to have resubmitted its application; as of October 2026, FDA has not announced a decision. Since July 2023, specially authorized psychiatrists in Australia can prescribe MDMA for PTSD, and a 2024 Utah law (SB 266) allows a limited hospital-based pilot program. Researchers think MDMA may work by quieting the brain's fear response while therapy helps people revisit and reprocess traumatic memories.

Traditional Use

No traditional indigenous use; MDMA was first synthesized by Merck in 1912. It gained therapeutic use in psychotherapy during the 1970s-80s before being scheduled.

Therapeutic Applications

Post-traumatic stress disorder (PTSD)Complex traumaSocial anxiety in autistic adults (early research)Alcohol use disorder (early research)

Clinical Trials

MAPP1

Completed - FDA Declined Approval August 2024
PhasePhase 3
InstitutionMAPS/Lykos Therapeutics

MAPP2

Completed - FDA Declined Approval August 2024
PhasePhase 3
InstitutionMAPS/Lykos Therapeutics

MDMA-Assisted Massed Prolonged Exposure

Ongoing
PhasePilot
InstitutionVA San Diego Healthcare System

MDMA for Social Anxiety in Autistic Adults

Completed - Positive Results
PhasePhase 2
InstitutionHarbor-UCLA

Risks & Contraindications

Potential Risks

  • •Temporary increase in heart rate and blood pressure
  • •Risk of overheating and dehydration
  • •Post-session mood depletion (serotonin depletion)
  • •Jaw clenching and teeth grinding
  • •Potential neurotoxicity with repeated recreational use
  • •Contraindicated with certain medications (MAOIs, SSRIs)

Contraindications

  • Cardiovascular disease
  • Uncontrolled hypertension
  • Liver or kidney disease
  • History of heat stroke
  • Concurrent MAOI or SSRI use
  • Pregnancy and breastfeeding
  • History of psychosis

Safety screening

Psychedelics are not safe for everyone. Talk with a licensed clinician first, especially if any of these apply to you:

  • Antidepressants such as SSRIs and SNRIs, and other medicines that raise serotonin (tramadol, for example): they can blunt the effect of psychedelics, and with some substances, such as MDMA and ayahuasca, raise the risk of serotonin syndrome.
  • Lithium: seizures have been reported when lithium is combined with classic psychedelics such as psilocybin and LSD.
  • MAOIs, including the MAOIs in ayahuasca: dangerous interactions with many medicines, other substances and some foods.
  • Heart disease, high blood pressure, or a heart rhythm problem such as long QT syndrome.
  • A personal or family history of psychosis, schizophrenia or bipolar disorder.
  • Pregnancy or breastfeeding.

Never stop or change a prescribed medicine without your prescriber.

Gabriel doesn't give psychedelic dosing and doesn't help anyone obtain psychedelics. This page explains research and risks; it is not medical advice.

If you're in crisis, call or text 988 (Suicide and Crisis Lifeline). For a medical emergency, call 911.

Legal Status

Legal status as of October 2026. Laws change; check the current law where you live. This is not legal advice.

United States

Schedule I federally and not FDA-approved as of October 2026. A 2024 Utah law (SB 266) allows a limited hospital-based pilot program using MDMA and psilocybin.

International

Since July 2023, specially authorized psychiatrists in Australia can prescribe MDMA for PTSD. Schedule I or equivalent in most other countries.

Key Researchers

Rick Doblin (MAPS founder)Michael Mithoefer (MAPS)Rachel Yehuda (Mount Sinai)Alicia Danforth (Harbor-UCLA)Ben Sessa (Imperial College London)

Key Studies

  • 1Mitchell et al. - MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021)
  • 2Mithoefer et al. - The safety and efficacy of MDMA-assisted psychotherapy in subjects with chronic, treatment-resistant PTSD (2011)
  • 3Danforth et al. - Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults (2018)

Quick Facts

CategoryEmpathogen
Evidence TierStrong
Duration3-5 hours peak effects, with aftereffects lasting 6-8 hours

Questions? Ask Gabriel

Gabriel can help you find and book licensed clinicians who offer ketamine or esketamine treatment. Gabriel doesn't prescribe ketamine.

Ask Gabriel